Zobrazeno 1 - 4
of 4
pro vyhledávání: '"LIVA S.L. KROGH"'
Autor:
Bolette Hartmann, Liva S.L. Krogh, Filip K. Knop, Mette M. Rosenkilde, Alexander Hovard Sparre-Ulrich, Tina Vilsbøll, Kirsa Skov-Jeppesen, Jens J. Holst, Mette H. Jensen, Mikkel B. Christensen, Flemming Dela, Lærke S. Gasbjerg, Signe Stensen
Publikováno v:
Stensen, S, Gasbjerg, L S, Krogh, L L, Skov-Jeppesen, K, Sparre-Ulrich, A H, Jensen, M H, Dela, F, Hartmann, B, Vilsbøll, T, Holst, J J, Rosenkilde, M M, Christensen, M B & Knop, F K 2021, ' Effects of endogenous GIP in patients with type 2 diabetes ', European Journal of Endocrinology, vol. 185, no. 1, pp. 33-45 . https://doi.org/10.1530/EJE-21-0135
Objective The insulinotropic effect of exogenous, intravenously infused glucose-dependent insulinotropic polypeptide (GIP) is impaired in patients with type 2 diabetes. We evaluated the effects of endogenous GIP in relation to glucose and bone metabo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbf5ca0367b3c3458d200af3686a07ef
https://doi.org/10.1530/eje-21-0135
https://doi.org/10.1530/eje-21-0135
Autor:
LÆRKE S. GASBJERG, MADS M. HELSTED, SIGNE STENSEN, LIVA S.L. KROGH, ALEXANDER H. SPARRE-ULRICH, BOLETTE HARTMANN, TINA VILSBØLL, MIKKEL B. CHRISTENSEN, JENS J. HOLST, CHRISTINA CHRISTOFFERSEN, FILIP K. KNOP, METTE M. ROSENKILDE
Publikováno v:
Diabetes. 71
The gut hormone glucose-dependent insulinotropic polypeptide (GIP) stimulates glucose-induced insulin secretion and increases triglyceride deposition in subcutaneous adipose tissue, and these effects are attenuated in both type 2 diabetes (T2D) and o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eefff882db827dff4028ed840820d89d
https://doi.org/10.2337/db22-1362-p
https://doi.org/10.2337/db22-1362-p
Autor:
Bolette Hartmann, Mikkel B. Christensen, Tina Vilsbøll, Natasha C. Bergmann, Asger Lund, Liva S.L. Krogh, Jens J. Holst, Lene Jessen, Filip K. Knop, Flemming Dela, Lærke S. Gasbjerg, Sebastian M. Nguyen Heimbürger
Publikováno v:
Diabetes Care. 43:588-596
OBJECTIVE Dual incretin receptor agonists in clinical development have shown reductions in body weight and hemoglobin A1c (HbA1c) in patients with type 2 diabetes, but the impact of glucose-dependent insulinotropic polypeptide (GIP) receptor activati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c43580b51b55666475a99c3d6e47de9
https://doi.org/10.2337/dc19-0578
https://doi.org/10.2337/dc19-0578
Autor:
Bolette Hartmann, Mette M. Rosenkilde, Tina Vilsbøll, Filip K. Knop, Liva S.L. Krogh, Jens J. Holst, Lærke S. Gasbjerg, Kirsa Skov-Jeppesen, Signe Stensen
Publikováno v:
Diabetes. 68
The gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) circulates in at least two active forms: GIP(1-42), which besides its insulinotropic effect during hyperglycemia stimulates glucagon secretion at low plasma glucose (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::921067996589bd91393418b710f4193b
https://doi.org/10.2337/db19-1976-p
https://doi.org/10.2337/db19-1976-p